Involvement of galectin-3 expression in colorectal cancer progression and metastasis.

Nakamura, Masato; Inufusa, Haruhiko; Adachi, Teppei; Aga, Mitsuharu; Kurimoto, Masayuki; Nakatani, Yoichiro; Wakano, Tsukasa; Nakajima, Ayako; Hida, Jin‐ichi; Miyake, Masayuki; Shindo, Katsuhisa; Yasutomi, Masayuki

doi:10.3892/ijo.15.1.143

Cited by 62 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the peptide recognised by the anti-hC4.4A-N antibody has a potential Nglycosylation site at AA position 129 and the peptide recognised by the anti-hC4.4A-C antibody is near a potential O-glycosylation site (Hansen et al, 2004). We previously described that C4.4A interacts with galectin-3 , which is associated with colorectal cancer progression (Schoeppner et al, 1995;Nakamura et al, 1999;Endo et al, 2005). The interaction of galectin-3 with its cellular ligands depends on the glycosylation status of the interaction partner (Barondes et al, 1994).…”

Section: Discussionmentioning

confidence: 99%

C4.4A as a candidate marker in the diagnosis of colorectal cancer

et al. 2007

View full text Add to dashboard Cite

C4.4A is a member of the Ly-6 family with restricted expression in non-transformed tissues. C4.4A expression in human cancer has rarely been evaluated. Thus, it became important to explore C4.4A protein expression in human tumour tissue to obtain an estimate on the frequency of expression and the correlation with tumour progression, the study focusing on colorectal cancer. The analysis of C4.4A in human tumour lines by western blot and immunoprecipitation using polyclonal rabbit antibodies that recognize different C4.4A epitopes revealed C4.4A oligomer and heavily glycosylated C4.4A isoform expression that, in some instances, inhibited antibody binding and interaction with the C4.4A ligand galectin-3. In addition, tumour cell lines released C4.4A by vesicle shedding and proteolytic cleavage. C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible expression in adjacent colonic mucosa, inflamed colonic tissue and liver. This compares well with EpCAM and CO-029 expression in over 90% of colorectal cancer. C4.4A expression was only observed in about 50% of pancreatic cancer and renal cell carcinoma. By de novo expression in colonic cancer tissue, we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids.

show abstract

Section: Discussionmentioning

confidence: 99%

C4.4A as a candidate marker in the diagnosis of colorectal cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…They are expressed both inside and outside cells and play important roles in a variety of cellular biological processes (8)(9)(10)(11), including various stages of tumor progression and/or malignancy (12,13). galectin-1, galectin-3, and galectin-4 appear to be involved in the early development of human colon carcinoma (14) and the malignant transformation of the tumor (15). especially, galectin-1 and galectin-3 play a role in the regulation of cell migration (16).…”

Section: Clinical Significance Of Circulating Galectins As Colorectalmentioning

confidence: 99%

Clinical significance of circulating galectins as colorectal cancer markers

et al. 2011

View full text Add to dashboard Cite

Abstract. the utility of ceA and cA19-9 as colorectal carcinoma (crc) markers is limited and development of additional reliable markers is under investigation. We previously showed that galectin-1 is overexpressed in crc tissues. If such a protein leaks into the peripheral circulation, it might constitute a tumor marker candidate. Here, we test the hypothesis that the levels of circulating galectins could reflect the presence of crc and/or its progression state. We constructed sandwich elIsAs for galectin-1/-2/-3/-4/-7 and determined their plasma concentrations in 105 crc patients and 100 healthy volunteers (control). Matched pair samples of 56 patients pre-and post-surgery were also subjected to elIsA analysis. circulating levels of galectin-1/-3/-4 in crc patients were significantly higher compared to those in controls. Galectin-1 and galectin-4 levels significantly decreased after surgery (p<0.01), and the level of galectin-4 in most patients fell below the cut-off value. the levels of circulating galectin-4 significantly increased as the tumor stage progressed (P<0.001), whereas those for galectin-1 were relatively high from an early stage. combined use of galectin-4 with ceA and/or cA19-9 markedly increased the proportion of crc patients who were positive for tumor markers (from 33.3 to 59.0% for ceA and from 17.1 to 51.4% for cA19-9). our data show that galectin-4 may be a tumor marker for use in patient follow-up, while galectin-1 could be used for tumor screening. In particular, galectin-4 can be useful as a complementary marker when combined with ceA/cA19-9 to improve crc follow-up.

show abstract

“…A large body of evidence has confirmed that metastatic cancer cells significantly express galectin-3, and high expression of galectin-3 can be detected in both primary and metastatic lesions [14] , even in blood [15] , showing a strong relation with cancer growth and metastasis [16][17][18] . Moreover, the expression of galectin-3 can be used as a diagnostic and prognostic marker of colorectal cancer [19][20][21] . Therefore, if the function of galectin-3 is blocked, the progression of adhesion and aggregation can be intercepted, which may stimulate the development of novel drugs for the targeted treatment of colorectal cancer and other cancers [22] .…”

Section: Discussionmentioning

confidence: 99%

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model

Liu

Huang²,

Yang³

et al. 2008

WJG

View full text Add to dashboard Cite

and MCP treatment groups was significantly higher than that in the negative control group. However, there was no significant difference between them. Except for the negative control group, the expression of galectin-3 in liver metastases of the other 4 groups showed no significant difference. CONCLUSION: Expression of galectin-3 increases significantly in liver metastasis of colon cancer, which can be effectively inhibited by MCP.

show abstract

Involvement of galectin-3 expression in colorectal cancer progression and metastasis.

Cited by 62 publications

References 0 publications

C4.4A as a candidate marker in the diagnosis of colorectal cancer

C4.4A as a candidate marker in the diagnosis of colorectal cancer

Clinical significance of circulating galectins as colorectal cancer markers

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model

Contact Info

Product

Resources

About